Constellation Pharmaceuticals, Inc

Short Term Long Term Short Term Comparison Long Term Comparison
  • CNST
  • 1d0.00%
  • 1w0.09%
  • 1m0.89%
  • 1y19.26%
ATH
  • ATH Price$49.79
  • ATH Date2020-05-12
  • % since ATH-31.73%
  • % to ATH46.48%
ATL
  • ATL Price$4.01
  • ATL Date2018-12-31
  • % from ATL747.63%
  • Last Low Price$17.62
  • Last Low Date2020-09-23
  • % From Last Low92.91%
IPO
  • IPO Price$11.48
  • % Current ROI USD296.08%
  • ATH Price$49.79
  • % ROI ATH 124,164.59%
[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="CNST"]

Key Data [addtoany]

Current price $33.99
Sector Healthcare
Industry Biotechnology
Today's High/Low $33.99/$33.99
Volume 0.00
Previous Close $33.99
52 Week High/Low $39.3/$17
Market Cap 1,630,354,176.00
P/E Ratio 0
Forward P/E 1 Yr. $0.00
Earnings Per Share(EPS) $-3.85
Annualized Dividend $0
$33.99
[addtoany]

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance.
The company’s lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib.
It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Annual Data | Millions of US $ except per share data 2019-12-312018-12-312017-12-312016-12-31
Cash on hand $383.93$114.59$16.40$36.92
Receivables ----
Inventory ----
Pre-Paid Expenses ----
Other Current Assets --$1.32$0.52
Total Current Assets $386.99$117.30$17.72$37.44
Property, Plant, And Equipment $11.72$1.21$1.12$1.03
Long-Term Investments ----
Goodwill And Intangible Assets ----
Other Long-Term Assets $0.43$0.43$0.26$0.24
Total Long-Term Assets $12.14$1.64$1.38$1.27
Total Assets $399.13$118.94$19.10$38.70
Total Current Liabilities $22.76$14.66$11.13$12.05
Long Term Debt $29.64-$0.25$4.10
Other Non-Current Liabilities $0.39$0.12$0.32$0.26
Total Long Term Liabilities $38.79$0.12$0.58$9.33
Total Liabilities $61.55$14.78$11.71$21.38
Common Stock Net $0400000$0300000$0100000$0100000
Retained Earnings (Accumulated Deficit) $-319.39$-233.84$-173.91$-138.54
Comprehensive Income ----
Other Share Holders Equity $-0600000---
Share Holder Equity $337.58$104.16$7.40$17.33
Total Liabilities And Share Holders Equity ----